Key result
Targeting NADPH oxidase-driven oxidative stress with agents like dapagliflozin, daidzein, and Shengmai San offers a promising therapeutic strategy for mitigating diabetic cardiomyopathy.
Why the study?
Despite the recognition of NADPH oxidase enzymes as crucial mediators in diabetic cardiomyopathy, therapeutic options specifically targeting NOX-driven oxidative stress remain limited.
Design
Comprehensive review
Authors
Loading...
NOX inhibition may offer a therapeutic avenue in diabetic cardiomyopathy; leaves open confirmation of clinical benefit in trials.
Targeting NOX-dependent oxidative stress, particularly through isoform-specific NOX inhibitors, represents a promising therapeutic strategy for diabetic cardiomyopathy.
Ye et al. (2025) conducted a review in Diabetic cardiomyopathy. NADPH oxidase (NOX) targeted therapies was evaluated. Targeting NADPH oxidase-driven oxidative stress with agents like dapagliflozin, daidzein, and Shengmai San offers a promising therapeutic strategy for mitigating diabetic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: